×

Bausch + Lomb eye-drop drug misses mid-stage study main goal

By Thomson Reuters Nov 19, 2026 | 3:49 PM

Nov 19 (Reuters) – Bausch + Lomb said on Thursday its experimental eye-drop treatment failed to meet the primary goal of a mid-stage study in ​patients with pain following laser eye surgery, ‌but showed signs of reducing pain and speeding corneal healing, findings the company said could support further development.

The contact lens maker said it plans to discuss the results with the ‌US ​Food and Drug Administration as ⁠it considers next steps ⁠for the drug, including a potential late-stage trial.

Here are some details:

• The mid-stage trial tested two doses of BL1332 in 129 patients undergoing photorefractive keratectomy, ​or PRK, a laser procedure used to correct vision

• US-listed shares of the eye-care company were ⁠down nearly 4% in extended ⁠trading

• Ocular surface pain is a ​common complication of eye surgery and certain eye diseases, and ​there are currently no approved treatments that ‌directly target its underlying nerve pathways, the company said

• The study missed its primary goal of significantly reducing pain during the first 24 hours after surgery ⁠compared with placebo

• However, both doses of BL1332 showed greater pain relief than placebo across all pain measures assessed ⁠in the trial, ‌the company said

• At six hours ⁠after surgery, complete pain relief was ​reported by ‌14% and 14.6% of patients receiving ​the two ⁠BL1332 doses, compared with 3.7% of patients receiving placebo

• The company also said patients treated with BL1332 showed signs of faster healing of the cornea, the eye’s outer surface

(Reporting by Siddhi Mahatole in Bengaluru; Editing ​by Tasim Zahid)